Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has filed a registration statement with the Securities and Exchange Commission (SEC) on April 12, 2024, for a Form S-3 registration statement under the Securities Act of 1933. This filing pertains to the resale of up to 2,369,000 shares of common stock by Selling Stockholders, which includes shares issuable upon the exercise of Series C Common Warrants and Placement Agent Warrants. The Selling Stockholders include certain investors and designees of H.C. Wainwright & Co., LLC, the placement agent in connection with a private placement transaction that closed on March 6, 2024. The registration of these shares does not necessarily mean that the Selling Stockholders will sell their shares, nor does it guarantee that any proceeds from the sale will be received by Adial Pharmaceuticals. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'ADIL'. The filing of this registration statement is part of Adial Pharmaceuticals' contractual obligations to provide for the resale by the Selling Stockholders of the shares of common stock offered.

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has filed a registration statement with the Securities and Exchange Commission (SEC) on April 12, 2024, for a Form S-3 registration statement under the Securities Act of 1933. This filing pertains to the resale of up to 2,369,000 shares of common stock by Selling Stockholders, which includes shares issuable upon the exercise of Series C Common Warrants and Placement Agent Warrants. The Selling Stockholders include certain investors and designees of H.C. Wainwright & Co., LLC, the placement agent in connection with a private placement transaction that closed on March 6, 2024. The registration of these shares does not necessarily mean that the Selling Stockholders will sell their shares, nor does it guarantee that any proceeds from the sale will be received by Adial Pharmaceuticals. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'ADIL'. The filing of this registration statement is part of Adial Pharmaceuticals' contractual obligations to provide for the resale by the Selling Stockholders of the shares of common stock offered.